Skip to content
10-Q

Quarterly Report

CYTOSORBENTS CORPORATION CTSO

0001104659-26-060270

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 62.79M sh
Shares Diluted Q1 2026 · Mar 31, 2026 62.74M sh
Shares Diluted Q1 2026 · Mar 31, 2025 60.73M sh
Capex Q1 2026 · Mar 31, 2026 $11K
Capex restated Q1 2026 · Mar 31, 2025 $2K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.16M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$3.47M
Long Term Debt Q1 2026 · Mar 31, 2026 $10.31M
Long Term Debt Q1 2026 · Dec 31, 2025 $16.67M
Short Term Debt Q1 2026 · Mar 31, 2026 $6.65M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4.81M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $6.25M
Stockholders Equity Q1 2026 · Mar 31, 2026 $2.19M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.9M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $14.54M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 $11.11M
Current Liabilities Q1 2026 · Mar 31, 2026 $16.3M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.71M
Total Liabilities Q1 2026 · Mar 31, 2026 $38.37M
Total Liabilities Q1 2026 · Dec 31, 2025 $38.28M
Current Assets Q1 2026 · Mar 31, 2026 $17.76M
Current Assets Q1 2026 · Dec 31, 2025 $20.63M
Total Assets Q1 2026 · Mar 31, 2026 $40.56M
Total Assets Q1 2026 · Dec 31, 2025 $44.18M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.02
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.02
Sga Expense Q1 2026 · Mar 31, 2026 $8.15M
Sga Expense restated Q1 2026 · Mar 31, 2025 $8.43M
Rd Expense Q1 2026 · Mar 31, 2026 $1.03M
Rd Expense Q1 2026 · Mar 31, 2025 $1.66M
Net Income Q1 2026 · Mar 31, 2026 −$5.13M
Net Income restated Q1 2026 · Mar 31, 2025 −$1.48M
Operating Income Q1 2026 · Mar 31, 2026 −$3.04M
Operating Income restated Q1 2026 · Mar 31, 2025 −$3.89M
Gross Profit Q1 2026 · Mar 31, 2026 $6.13M
Gross Profit restated Q1 2026 · Mar 31, 2025 $6.21M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $2.73M
Cost Of Revenue restated Q1 2026 · Mar 31, 2025 $2.52M